OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Headache and Pain is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine	473
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition	234
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis	149
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II	108
Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description	103
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study	101
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency	87
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study	82
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	73
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	67
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study	63
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials	59
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	57
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan	57
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache	55
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study	54
Characteristics of N400 component elicited in patients who have migraine with aura	51
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks	49
Debate: Are cluster headache and migraine distinct headache disorders?	48
Measuring interictal burden among people affected by migraine: a descriptive survey study	48
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke	47
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	46
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	45
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia	45
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	43

Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome	42
Primary headaches during the COVID-19 lockdown in Germany: analysis of data from 2325 patients using an electronic headache diary	41
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine	40
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China	39
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey	39
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States	37
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI	36
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial	36
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study	35
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury	34
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results	34